Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICC-1132
- Development stage
- Phase 1
- Lead developer
- PATH Malaria Vaccine Initiative
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ICC-1132 is a recombinant virus-like particle malaria vaccine candidate composed of a modified hepatitis B virus core particle (HBc) engineered to express protective epitopes from the circumsporozoite (CS) protein of Plasmodium falciparum. The vaccine contains both B-cell epitopes (NANP)3 from the CS repeat region and T-cell epitopes, including HLA-restricted CD4+ T-cell epitopes (NANPNVDP), a universal T-cell epitope (T*) from the carboxyl terminus of CS, and at least one CD8+ T-cell epitope. When expressed in Escherichia coli, the recombinant protein forms virus-like particles designed to elicit strong immune responses against malaria.
- Brand names
- MalariVax
02
Targets
HBc (Hepatitis B virus core protein)TCR-PfCSP (T-cell receptor recognizing Plasmodium falciparum circumsporozoite protein epitopes)Plasmodium falciparum circumsporozoite protein-specific B-cell receptor and antibody
Beyond the preview
Go deeper on ICC-1132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICC-1132.